JPM vs JQC

JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.

JQC presents a conflicting profile with a stable Piotroski F-Score of 4/9 but severe fundamental deterioration. While the stock trades below its Graham Number ($5.88) and at a discount to book value (P/B 0.87), these value metrics are overshadowed by a catastrophic earnings collapse of -45.70% YoY. Most critically, the dividend payout ratio of 229.20% is unsustainable, indicating the fund is returning capital or using leverage rather than earnings to maintain its 12.38% yield. The stark divergence between the Graham Number and the growth-based Intrinsic Value ($1.96) reflects a business in structural decline.